Oncotarget

Research Papers:

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy

Fenne L. Komdeur, Maartje C.A. Wouters, Hagma H. Workel, Aline M. Tijans, Anouk L.J. Terwindt, Kim L. Brunekreeft, Annechien Plat, Harry G. Klip, Florine A. Eggink, Ninke Leffers, Wijnand Helfrich, Douwe F. Samplonius, Edwin Bremer, G. Bea A. Wisman, Toos Daemen, Evelien W. Duiker, Harry Hollema, Hans W. Nijman _ and Marco de Bruyn

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:75130-75144. https://doi.org/10.18632/oncotarget.12077

Metrics: PDF 1339 views  |   HTML 1635 views  |   ?  


Abstract

Fenne L. Komdeur1,*, Maartje C.A. Wouters1,2,*, Hagma H. Workel1, Aline M. Tijans1, Anouk L.J. Terwindt1, Kim L. Brunekreeft1, Annechien Plat1, Harry G. Klip1, Florine A. Eggink1, Ninke Leffers1, Wijnand Helfrich3, Douwe F. Samplonius3, Edwin Bremer3, G. Bea A. Wisman1, Toos Daemen2, Evelien W. Duiker4, Harry Hollema4, Hans W. Nijman1,#, Marco de Bruyn1,#

1University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands

2University of Groningen, University Medical Center Groningen, Department of Medical Microbiology, The Netherlands

3University of Groningen, University Medical Center Groningen, Department of Surgery, The Netherlands

4University of Groningen, University Medical Center Groningen, Department of Pathology, The Netherlands

*These authors have contributed equally to this work

#MB and HWN share senior authorship

Correspondence to:

Hans W. Nijman, email: h.w.nijman@umcg.nl

Keywords: tumor-infiltrating lymphocytes, high-grade serous ovarian cancer, CD103, TGF-β, cancer immunotherapy

Received: May 06, 2016    Accepted: September 02, 2016    Published: September 16, 2016

ABSTRACT

CD103+ tumor-infiltrating lymphocytes (TIL) have been linked to specific epithelial infiltration and a prolonged survival in high-grade serous epithelial ovarian cancer (HGSC). However, whether these cells are induced as part of an ongoing anti-HGSC immune response or represent non-specifically expanded resident or mucosal lymphocytes remains largely unknown. In this study, we first confirmed that CD103+ TIL from HGSC were predominantly localized in the cancer epithelium and were strongly correlated with an improved prognosis. We further demonstrate that CD103+ TIL were almost exclusively CD3+ TCRαβ+ CD8αβ+ CD4- T cells, but heterogeneously expressed T cell memory and differentiation markers. Activation of peripheral T cells in the presence of HGSC was sufficient to trigger induction of CD103 in over 90% of all CD8+ cells in a T cell receptor (TCR)- and TGFβR1-dependent manner. Finally, CD103+ TIL isolated from primary HGSC showed signs of recent activation and dominantly co-expressed key immunotherapeutic targets PD-1 and CD27. Taken together, our data indicate CD103+ TIL in HGSC are formed as the result of an adaptive anti-tumor immune response that might be reactivated by (dual) checkpoint inhibition.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12077